Progyny, Inc. reports developments in women's health and family building benefits, including fertility care access, employer demand, product expansion, and financial results. The company provides benefit solutions for employers, health plans, and benefit purchasers, combining concierge support, coaching, education, digital tools, and access to a network of fertility and women's health specialists.
Recurring updates include quarterly earnings, financial guidance, selling-season activity, share repurchases, investor conference appearances, and offerings such as Progyny Select, a fully insured supplemental fertility and family building plan for small U.S. employers.
Progyny (Nasdaq: PGNY), a top benefits management company in fertility and family building solutions, announced that CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:50 P.M. ET. This event aims to discuss Progyny's innovative approach to fertility benefits, highlighting its comprehensive solutions that benefit employers, patients, and physicians. A live audiocast and replay will be accessible on their official website.
Progyny, Inc. (PGNY) reported record revenues of $500.6 million for 2021, marking a 45% growth year-over-year. The fourth quarter revenue reached $127.6 million, up 27%, driven by a significant increase in clients. Despite the impact of the COVID-19 Omicron variant, the company maintained a high retention rate and successful sales season. However, net income in Q4 decreased to $15.1 million from $39.1 million the previous year, primarily due to a lower tax benefit. Looking ahead, 2022 guidance forecasts revenue of $730 million to $775 million, reflecting 46% to 55% growth.
Progyny, Inc. (Nasdaq: PGNY) will announce its financial results for the quarterly period and full year ending December 31, 2021, on February 28, 2022. A conference call will be held at 4:45 PM ET to discuss the results, with access details provided for U.S. and international participants. An audio replay will be available until March 7, 2022. Progyny specializes in fertility and family building benefits, focusing on education and access to specialists while reducing costs for employers. The company has received recognition for its growth and leadership in the sector.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced its CEO, Pete Anevski, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 A.M. ET. The presentation will be followed by a breakout session featuring President Michael Sturmer and CFO Mark Livingston. A live audiocast and replay will be accessible on Progyny's website. Progyny is recognized for its innovative fertility solutions that benefit patients, employers, and healthcare providers alike.
Progyny (PGNY) reported a strong third quarter of 2021, with revenues of $122.3 million, marking a 24% increase year-over-year. The company added over 85 new clients, resulting in approximately 1.2 million new covered lives. Gross profit rose to $28.5 million with a gross margin of 23.3%, up from 21.1% in the previous year. Net income reached $16.8 million, a significant increase from $4.8 million last year. For 2022, Progyny anticipates revenue growth of about 50%, driven by new client launches.
Progyny, Inc. (Nasdaq: PGNY) is set to release its financial results for the quarter ending September 30, 2021, on November 4, 2021, after market close. A conference call will follow at 4:45 PM ET, during which the company will discuss its results. Participants can join by dialing the provided numbers. An audio replay will be available until November 11, 2021. Progyny specializes in fertility and family-building benefits, focusing on comprehensive solutions that benefit employers, patients, and healthcare providers.
Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and CFO Mark Livingston will participate in a fireside chat at the BofA Global Healthcare Conference on September 15, 2021, at 10:55 A.M. ET. The event will be accessible via a live audiocast on Progyny’s website. Progyny aims to redefine fertility and family building benefits, enhancing access to comprehensive care and reducing healthcare costs for employers. The company has received multiple recognitions for its growth and leadership.
Castlight Health (NYSE: CSLT) has announced the addition of four new partners to its digital health ecosystem, aimed at addressing employee health challenges intensified by the pandemic. The new partners include Spring Health, WW, SWORD Health, and Progyny (NASDAQ: PGNY), enhancing Castlight's offerings in mental health, weight management, and fertility solutions. These partnerships will provide a unified platform for employers to support workforce health, improving engagement through integrated services and two-way data sharing, which typically boosts engagement by 45-55%.
Progyny, a prominent fertility benefits management company, announces that CEO David Schlanger will participate in a fireside chat at the BofA Securities SMID Cap 2H21 Ideas Conference on August 10, 2021, at 1:00 PM ET. A live audiocast and replay will be accessible on Progyny's website. Progyny aims to enhance fertility solutions for employers and patients through dedicated support and a network of specialists. The company has received accolades for its growth and innovation in the healthcare sector.
Progyny, Inc. (PGNY) reported record second quarter revenue of $128.7 million, reflecting a remarkable 99% growth year-over-year. The surge in demand for fertility benefits led to increased client numbers, with 182 clients as of June 30, 2021. Gross profit reached $29.6 million, a 148% increase, while net income soared to $18.7 million, compared to a loss in the prior year. The company anticipates revenue of $510 million to $530 million for the full year 2021, marking a projected 48% to 54% growth.